Urokinase Pregnancy and Breastfeeding Warnings

Brand names: Abbokinase, Abbokinase Open-Cath, Kinlytic

Medically reviewed by Drugs.com. Last updated on Feb 21, 2025.

Urokinase Pregnancy Warnings

Should not be given during pregnancy or in the immediate postpartum unless it is clearly needed.

AU TGA pregnancy category: B1
US FDA pregnancy category: B

Comment: There is limited amount of data on the use of this drug in pregnancy.

Animal studies have failed to reveal evidence of fetal harm. There are no controlled data in human pregnancy.

AU TGA pregnancy category B1: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have not shown evidence of an increased occurrence of fetal damage.

US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.

See references

Urokinase Breastfeeding Warnings

Breastfeeding should be avoided during use of this drug.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments: The effects in the nursing infant are unknown.

See references

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer